Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea; ECO lab, SK plasma, Seongnam 13494, Republic of Korea.
Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
J Chromatogr B Analyt Technol Biomed Life Sci. 2024 May 1;1238:124111. doi: 10.1016/j.jchromb.2024.124111. Epub 2024 Mar 30.
Adiponectin, a crucial protein hormone originating from adipose tissue, regulates key metabolic processes, including lipid metabolism, mitochondrial activity, and insulin sensitivity. These pleiotropic roles of adiponectin, along with its inverse correlation with metabolic disorders such as obesity, type II diabetes, and atherosclerosis, establish this protein as a potential therapeutic target. However, due to this complexity, challenges have arisen in its production with a natural conformation in bacterial or mammalian expression systems, hindering clinical translation. Furthermore, while inducers for adiponectin secretion or chemical agonists targeting adiponectin receptors have shown promise in laboratory settings, clinical studies with these agents have not yet been conducted. This study proposes a method for isolating and purifying natural high molecular weight (HMW) adiponectin from discarded plasma fractions during the conventional pharmaceutical protein manufacturing process. The process involved Cohn-Oncley fractionation, initial chromatography using reduced cellufine formyl, and subsequent purification via DEAE Sepharose chromatography. Characterization involved gel electrophoresis and biological assays on a hepatocyte cell-line. The purification process effectively captured adiponectin from the I + III paste, demonstrating that this fraction contained a significant portion of total plasma adiponectin. The two-step chromatography led to highly purified HMW adiponectin, confirmed by native-PAGE showing a 780 kDa multimeric complex. Biological assessments demonstrated normal downstream signaling, with HMW adiponectin inducing AMPK phosphorylation. This study demonstrates the feasibility of obtaining purified HMW adiponectin by repurposing plasma fractionation processes. It offers a promising avenue for the HMW adiponectin production, tapping into HMW adiponectin's therapeutic potential against metabolic disorders while optimizing plasma resource utilization in healthcare.
脂联素是一种源自脂肪组织的重要蛋白质激素,可调节包括脂质代谢、线粒体活性和胰岛素敏感性在内的关键代谢过程。脂联素的这些多效性作用,以及它与肥胖、2 型糖尿病和动脉粥样硬化等代谢紊乱的负相关关系,使这种蛋白质成为潜在的治疗靶点。然而,由于其复杂性,在细菌或哺乳动物表达系统中以天然构象生产这种蛋白遇到了挑战,阻碍了其临床转化。此外,尽管脂联素分泌的诱导剂或针对脂联素受体的化学激动剂在实验室环境中显示出了前景,但尚未在这些药物的临床试验中进行。本研究提出了一种从常规制药蛋白生产过程中废弃的血浆级分中分离和纯化天然高分子量(HMW)脂联素的方法。该方法包括 Cohn-Oncley 分步沉淀法、使用还原的纤维素甲酰基进行初始色谱分离,以及随后通过 DEAE 琼脂糖色谱进行纯化。特性鉴定包括凝胶电泳和对肝细胞系的生物学检测。该纯化过程有效地从 I+III 糊状物中捕获脂联素,表明该级分包含了总血浆脂联素的很大一部分。两步色谱法导致高度纯化的 HMW 脂联素,经 Native-PAGE 证实为 780 kDa 多聚体复合物。生物学评估表明正常的下游信号,HMW 脂联素诱导 AMPK 磷酸化。本研究证明了通过重新利用血浆分级过程获得纯化的 HMW 脂联素的可行性。它为 HMW 脂联素的生产提供了一个有前景的途径,利用 HMW 脂联素治疗代谢紊乱的治疗潜力,同时优化了医疗保健中血浆资源的利用。